Santiago Montes‐Moreno

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov et al. · Blood · 2013 · 671 citations · Full text

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Zijun Y. Xu‐Monette, Lin Wu, Carlo Visco et al. · Blood · 2012 · 383 citations · Full text

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Carlo Visco, Y Li, Zijun Y. Xu‐Monette et al. · Leukemia · 2012 · 354 citations

Hematological Malignancy, Lymphoid Neoplasia, Engineering +14

Primary Cutaneous CD4+ Small/Medium-sized Pleomorphic T-cell Lymphoma Expresses Follicular T-cell Markers

Socorro Marıá Rodríguez-Pinilla, Giovanna Roncador, José Luis Rodríguez‐­Peralto et al. · The American Journal of Surgical Pathology · 2008 · 247 citations

Cutaneous T-cell Lymphoma, Sixteen Cstcls, Lymphoid Neoplasia +13

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Shimin Hu, Zijun Y. Xu‐Monette, Aarthi Balasubramanyam et al. · Blood · 2013 · 243 citations · Full text